Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Regains Compliance With Nasdaq Listing Requirement

NEW YORK (GenomeWeb) – Signal Genetics said today that it has received a letter from Nasdaq notifying the company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement for continued listing.

The letter noted that as of Nov. 21 the company evidenced a closing bid price of its common stock in excess of the $1 minimum requirement for at least 10 consecutive trading days.

Earlier this month Signal and Miragen Therapeutics announced their plans to merge, to divest Signal's molecular diagnostic assets, and to form a company fully focused on Miragen's microRNA therapeutics programs.

As part of the deal, which is expected to close in the first quarter of 2017, privately held Miragen will pick up Signal's Nasdaq listing.